muscle cells (HPASMCs) contribute to the genesis and development of PAH. [3] [4] [5] Targeting vascular remodelling has been proposed as a strategy for the development novel therapies for PAH. 6 Therefore, it is necessary for us to understand the molecular mechanisms underlying the HPASMCs-mediated vascular remodelling.
MicroRNAs (miRNAs) are a class of small non-coding RNAs with 21-23 nucleotides in length, and miRNAs exerted the biological functions via targeting the 3′ untranslated region (3′UTR) of the genes to transcriptionally repress the gene expression. 7, 8 miRNAs are found to involve in many biological processes including cell proliferation, apoptosis, invasion, migration and metabolism. 9 To date, a large body of evidence has pointed to the functional role of miRNAs in the pathophysiology of PAH. Caruso et al showed that miR-124
was down-regulated in the pulmonary vascular and circulating progenitor endothelial cells from PAH patients, and dysregulation of miR-124 contributed to the endothelial cell glycolysis. 10 miR-4224
and miR-503 were found to mediate the link between endothelial apelin and fibroblast growth factor 2, which was disrupted in the PAH. 11 In addition, down-regulation of miR-126 contributed to the right ventricle failure in PAH and restoration miR-129 expression in the right ventricle improved micro-vessel density and right ventricle function in experimental PAH. 12 miR-629 was a newly identified miRNA and plays an oncogenic role in several types of cancers including cervical cancer, colorectal cancer, breast cancer and ovarian cancer. [13] [14] [15] [16] Despite the role of miR-629 in cancer, the role of miR-629 in PAH has not been investigated so far.
In this study, we identified the up-regulation of miR-629 in the HPASMCs under hypoxia conditions, and further in vitro functional studies showed that miR-629 exerted enhanced effects on the proliferation of HPASMCs, and mechanistic investigations demonstrated that miR-629 exerted its effects on cellular functions via regulating forkhead box O3 (FOXO3) and p53 apoptosis effector related to PMP-22 (PERP) in HPASMCs. The evidence in the present study provided a novel role of miR-629 in the hyper-proliferated HPASMCs, which may be associated with the development of PAH.
| MATERIAL S AND ME THODS

| Cell culture
The HPASMCs were obtained from Sigma-Aldrich (St. Louis, USA).
The cells were cultured in the smooth muscle cell growth medium (Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS;
Thermo Fisher Scientific, Waltham, USA). The cells were maintained in a humidified incubator with 5% CO 2 at 37°C. 
| Hypoxia treatment, oligo nucleotides and cell transfections
| Collection of plasma samples
| Quantitative real-time PCR
Total RNA from cells was extracted by using the TRIzol reagent (Invitrogen) according to the manufacturer's protocol. For the quantification of miR-629, cDNA was synthesized by the One Step Prime script miRNA cDNA synthesis kit (Qiagen, Valencia), and real-time PCR was performed using the miRNA-specific TaqMan MiRNA Assay Kit (Applied Biosystems, Foster City, USA) on an ABI7900 system (Applied Biosystems). For the mRNA detection, mRNA was reversely transcribed into cDNA using PrimeScript RT reagent kit (Takara, Dalian, China), and real-time PCR was performed using SYBR Green Premix Ex Taq II kit (Takara) on an ABI7900 system (Applied Biosystems). U6 and GAPDH were used as internal controls for miRNA and mRNA expression, respectively, and the relative expression of respective genes was calculated by 2 −ΔΔCt method.
| Western blot
Proteins from cells were extracted by the RIPA buffer (Bio-Rad, Hercules) supplemented with protease inhibitors (Sigma-Aldrich), and the concentrations of the extracted proteins were measured by BCA kit (Bio-Rad) according to the manufacturer's protocol. The equal amounts of proteins were resolved on a 10% SDS-PAGE, and after gel electrophoresis, the separated proteins were then transferred to the PVDF membranes. After being washed with PBST for three times, the membranes were incubated with 5% skimmed milk at room temperature for 1 hour, and the membranes were then subjected to incubation with different antibodies against proliferating cell nuclear antigen (PCNA), cleaved caspase-3, FOXO3, PERP and β-actin (Abcam, Cambridge) at 4°C overnight. Then, the membranes were washed with PBST for three times before incubating with the horseradish peroxidase-conjugated secondary antibodies (Abcam). After being washed with PBST for three times, the blots were detected by an enhanced chemiluminescence detection system (Bio-Rad) according to the manufacturer's protocol.
| Cell counting kit-8 assay
Cell viability of HPASMCs was detected by CCK-8 assay (Beyotime, Beijing, China). Briefly, the treated HPASMCs were incubated with 10 μl CCK-8 reagent for 2 hours at room temperature. The absorbance at a wavelength of 450 nm was determined by a microplate reader to assess the cell viability.
| Bromodeoxyuridine assay
Cell proliferation of HPASMCs was determined using the BrdU assay kit (Millipore, Billerica, USA) according to the manufacturer's protocol. Briefly, the treated HPASMCs were incubated with 10 μl BrdU reagent at room temperature for 5 hours followed by fixing with FixDeant for 30 minutes. Cells were then incubated with anti-BrdU antibody (Abcam) at 4°C overnight, followed by treatment with Cy5-conjugated secondary antibody for 2 hours. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (Sigma-Aldrich) for 15 minutes at room temperature. The BrdU activity was determined using a fluorescence confocal microscopy. 
| Cell migration assay
| Caspase-3 activity
For the measurement of the caspase-3 activity, the treated HPASMCs were subjected to caspase-3 activity determination using the Caspase-3 Assay Kit (Abcam) according to manufacturer's protocol.
| Luciferase reporter assay
The pGL3 vector (Promega, Madison, SUA) was used to construct the reporter vectors, and the fragment of wild-type 3′UTR of 
F I G U R E 1
The effects of hypoxia on miR-629 expression, cell viability and cell proliferation in HPASMCs. A, The expression of miR-629 in HPASMCs after being treated with hypoxia for 12, 24 and 48 h was determined by qRT-PCR. B, Cell viability of HPASMCs after being treated with hypoxia for 12, 24 and 48 h was determined by CCK-8 assay. C, Cell proliferation of HPASMCs after being treated with hypoxia for 12, 24 and 48 h was determined by BrdU assay. Data are expressed as mean ± standard deviation; n = 3. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control groups
| Statistical analysis
All the data were expressed as mean ± standard deviation. GraphPad Prism 6.0 (GraphPad Software, La Jolla) was used to perform the statistical analysis and graph plotting. Student's t test and one-way ANOVA were used for difference comparison between two groups or among more than two groups. Statistically significant differences were defined as P < 0.05.
| RE SULTS
| Hypoxia-induced miR-629 up-regulation, promoted cell viability and proliferation in HPASMCs
To address the effects of hypoxia on the miR-629 expression, cell viability and proliferation of HPASMCs, the HPASMCs were exposed to hypoxia for 12, 24 and 48 hours respectively. After hypoxia exposure, HPASMCs were subjected to qRT-PCR assay, CCK-8 assay and BrdU assay. As shown in Figure 1A , hypoxia treatment signifi- The caspase-3 activity and the expression of caspase-3 protein in HPASMCs after being transfected with mimics NC or miR-629 mimics were determined by Caspase-3 activity assay and western blot respectively. Data are expressed as mean ± standard deviation; n = 3. * P < 0.05, ** P < 0.01 and *** P < 0.001 versus control groups in miR-629 mimics-transfected HPASMCs compared to mimics NC group ( Figure 2F ). The effects of miR-629 on cell apoptosis were evaluated by caspase-3 activity and caspase-3 protein expression, and overexpression of miR-629 suppressed the caspase-3 activity and caused a decreased in the caspase-3 protein level ( Figure 2G ,H).
| Knockdown of miR-629 suppressed cell proliferation, cell migration and induced cell apoptosis of HPASMCs during hypoxia
The effects of miR-629 knockdown in hypoxia-treated HPAMSCs were also determined by performing in vitro functional assays. As shown in Figure 3A , transfection with miR-629 inhibitors significantly suppressed the expression of miR-629 in HPASMCs compared to mimics NC transfection ( Figure 3A) . Furthermore, HPASMCs were first exposed to hypoxia for 48 h, and then the effects of miR-629 on cell proliferation, migration and apoptosis were assessed. The caspase-3 activity and the expression of caspase-3 protein in hypoxia-treated HPASMCs after being transfected with inhibitors NC or miR-629 inhibitors were determined by Caspase-3 activity assay and western blot respectively. Data are expressed as mean ± standard deviation; n = 3. * P < 0.05, ** P < 0.01 and *** P < 0.001 versus control groups hypoxia-treated HPASMCs ( Figure 3F ). In terms of cell apoptosis, knockdown of miR-629 increased the caspase-3 activity and protein level of caspase-3 in hypoxia-treated HPASMCs ( Figure 3G ,H).
| MiR-629 directly targets FOXO3 and PERP
To address the mechanistic role of miR-629 in HPASMCs, we performed the bioinformatics prediction analysis using the targetscan software. Among these predicted targets, FOXO3 and PERP were further selected for our investigation. Figure 4A showed the pre- 
| Overexpression of FOXO3 and PERP reversed the effects of miR-629 overexpression on cell proliferation, migration and apoptosis of HPASMCs
To determine whether miR-629 exerted its effects via FOXO3
and PERP in HPASMCs, we performed the rescue experiments by HPASMCs ( Figure 6I ). The expression of PERP mRNA and protein in HPASMCs after exposing to hypoxia or normoxia was determined by qRT-PCR and western blot respectively. Data are expressed as mean ± standard deviation; n = 3. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control groups
| Overexpression of FOXO3 and PERP reversed the hypoxia-induced effects on cell proliferation, migration and apoptosis of HPASMCs
The rescue experiments were further performed to address if FOXO3
or PERP mediated the hypoxia-induced changes in the cellular functions of HPASMCs. As shown in Figure 7A -C, enforced expression of FOXO3 or PERP partially reversed the hypoxia-induced increase in cell viability, proliferation and expression level of PCNA mRNA in HPASMCs ( Figure 7A-C) . Consistently, hypoxia treatment increased the migratory potential of HPASMCs, and this effect was reversed by the enforced expression of FOXO3 or PERP ( Figure 7D ). In addition, enforced expression of FOXO3 or PERP also attenuated the suppressive effects of hypoxia treatment on the caspase-3 activity in HPASMCs ( Figure 7E ).
| The expression of miR-629, FOXO3 and PERP mRNA in clinical samples
The expression of miR-629, FOXO3 and PERP mRNA in the plasma from healthy controls and PAH patients was determined by qRT-PCR. The expression of PERP mRNA and protein in HPASMCs after being transfected with pcDNA3.1 or pcDNA3.1-PERP was determined by qRT-PCR and western blot respectively. (E) Cell viability and (F) cell proliferation of HPASMCs after being co-transfected with miRNAs and plasmids were determined by CCK-8 assay and BrdU assay respectively. G, The expression of PCNA mRNA in HPASMCs after being co-transfected with miRNAs and plasmids was determined by qRT-PCR. H, Cell migration of HPASMCs after being co-transfected with miRNAs and plasmids was measured by transwell migration assay. I, Cell migration of HPASMCs after being co-transfected with miRNAs and plasmids was measured by transwell migration assay. Data are expressed as mean ± standard deviation; n = 3. * P < 0.05, ** P < 0.01 and *** P < 0.001 versus control groups
As shown in Figure 8A , the expression of miR-629 was up-regulated in the plasma from PAH patients when compared to healthy controls. Consistently, the mRNA expression of FOXO3 and PERP was down-regulated in the plasma from PAH patients when compared to healthy controls ( Figure 8B ,C).
| D ISCUSS I ON
This study is the first, to our knowledge, to identify up-regulation of miR-629 in the in vitro experimental models of HPASMCs exposing to hypoxia. Treatment with miR-629 mimics promoted HPASMCs PAH and functioned as an important mediator in the miR-124-mediated proliferation of pulmonary vascular fibroblasts, 24 suggesting the potential role of FOXO3 in the pathophysiology of PAH. PERP was found to function as a p53 transcriptional target that is induced during apoptosis in response to DNA damage. 25 PERP was found to suppress tumour cell proliferation and promote cell apoptosis in various types of cancers. [26] [27] [28] Additionally, silencing of PERP was found to inhibit the cell apoptosis in hypoxia-mediated injury in renal cells. 29 As expected, our data showed that enforced expression of 
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